
Nykode Therapeutics Investor Relations Material
Latest events

Q1 2025
Nykode Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nykode Therapeutics
Access all reports
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company based in Oslo, Norway. The company focuses on the discovery and development of novel vaccines and immunotherapies, primarily targeting cancer and infectious diseases. Nykode leverages its proprietary modular vaccine technology, which directs antigens to antigen-presenting cells, aiming to induce strong and long-lasting immune responses. Its leading product candidates include VB10.16, a therapeutic vaccine in development for human papillomavirus (HPV)-related cancers, and VB10.NEO, a cancer neoantigen vaccine, which is in clinical trials for several types of advanced tumors. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Nykode Therapeutics


Q2 2024
Nykode Therapeutics


Q1 2025
Nykode Therapeutics
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
NYKD
Country
🇳🇴 Norway